3 late-stage assets, in 4 Phase 3 studies, with topline data expected across 2026 Mainstay biologic with science of immediacy and durability, on track for BLA filing in 2026 in 3 indications of wet AMD, DR and RVO Tarcocimab Anti-VEGF ABC ® Mainstay biologic with potential for additional efficacy beyond anti-VEGF monotherapies while maintaining immediacy and signature durability of ABC platform KSI-501 Anti-IL-6, VEGF trap bispecific ABC ® High-strength, dual inhibition of IL-6 and VEGF, for safe and potent control of macular edema secondary to inflammation (MESI) KSI-101 High-strength anti-IL-6, VEGF trap bispecific protein . ABC: antibody biopolymer conjugate; DR: diabetic retinopathy; RVO: retinal vein occlusion; AMD: age-related macular degeneration Quadrant of core unmet need Quadrant of core unmet need Greenfield market opportunity For patients with retinal vascular diseases For patients with MESI 11